A cost comparison of long-acting insulin analogs vs NPH insulin-based treatment in patients with type 2 diabetes using routinely collected primary care data from the UK

References

• Meier JJ, Bonadonna RC. Role of reduced β-cell mass versus impaired β-cell function in the pathogenesis of type 2 diabetes. Diabetes Care 2013;36(2 Suppl):S113-19
   PubMedGoogle Scholar
• Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
   PubMed Web of Science ®Google Scholar
• Janka HU, Hessel F, Walzer S, et al. Insulin glargine added to therapy with oral antidiabetic agents improves glycemic control and reduces long-term complications in patients with type 2 diabetes - a simulation with the Diabetes Mellitus Model (DMM). Int J Clin Pharmacol Ther 2007;45:623-30
   PubMed Web of Science ®Google Scholar
• González EL, Johansson S, Wallander MA, et al. Trends in the prevalence and incidence of diabetes in the UK: 1996–2005. J Epidemiol Community Health 2009;63:332-6
   PubMed Web of Science ®Google Scholar
• Gordon J, Evans M, McEwan P, et al. Evaluation of insulin use and value for money in type 2 diabetes in the United Kingdom. Diabetes Ther 2013;4:51-66
   PubMed Web of Science ®Google Scholar
• Holden SE, Poole CD, Morgan CL, et al. Evaluation of the incremental cost to the National Health Service of prescribing analogue insulin. BMJ Open 2011;1:e000258
   PubMed Web of Science ®Google Scholar
• Home PD, Fritsche A, Schinzel S, et al. Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine. Diabetes Obes Metab 2010;12:772-93
   PubMed Web of Science ®Google Scholar
• Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose- lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006;29:1269-74
   PubMed Web of Science ®Google Scholar
• NHS. Type 2 diabetes mellitus. 2013. http://www.nice.org.uk/advice/ktt12/resources/non-guidance-type-2-diabetes-mellitus-pdf
   Google Scholar
• QIPP. Cochrane quality and productivity topics. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. www.evidence.nhs.uk/qualityandproductivity. Accessed December 20, 2012
   Google Scholar
• Idris I, Hucknall B, Roshan M, Davies M, on behalf of the East Midlands SHA Diabetes QIPP workstream steering group. Cost analysis of prescribing analogue insulin should take into account the bigger picture of diabetes treatment prescribing cost. BMJ journals. 2011
   Google Scholar
• Rhoads GG, Dain MP, Zhang Q, et al. Two-year glycaemic control and healthcare expenditures following initiation of insulin glargine versus neutral protamine Hagedorn insulin in type 2 diabetes. Diabetes Obes Metab 2011;13:711-17
   PubMed Web of Science ®Google Scholar
• Schöffski O, Breitscheidel L, Benter U, et al. Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study. J Med Econ 2008;11:695-712
   PubMedGoogle Scholar
• The Institute for Translational Medicine and Therapeutics. A description of the THIN database. http://www.itmat.upenn.edu/ctsa/acard/docs/all_Description_THIN-FINAL.pdf. Accessed July 2014
   Google Scholar
• Joint Formulary Committee. British National Formulary. 63rd ed. London: BMJ Group and Pharmaceutical Press, 2012
   Google Scholar
• Netten A. Unit costs of health and social care. Canterbury: Personal Social Services Research Unit, University of Kent, 2011. http://www.pssru.ac.uk/pdf/uc/uc2011/uc2011.pdf. Accessed July 2014
   Google Scholar
• NHS reference cost schedules. http://www.dh.gov.uk/health/tag/reference-costs/. Accessed July 2014
   Google Scholar
• HM Treasury. GDP deflators: user guide. 2014. https://www.gov.uk/government/publications/gross-domestic-product-gdp-deflators-user-guide/gdp-deflators-user-guide. Accessed July 2014
   Google Scholar
• StataCorp. Stata statistical software: release 11 [program]. StataCorp, 2009
   Google Scholar
• Lee LJ, Yu AP, Johnson SJ, et al. Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: a retrospective database analysis. Diabetes Res Clin Pract 2010;87:108-16
   PubMed Web of Science ®Google Scholar
• Riddle MC, Rosenstock J, Gerich J. Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-6
   PubMed Web of Science ®Google Scholar
• Fidler C, Elmelund Christensen T, Gillard S. Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs. J Med Econ 2011;14:646-55
   PubMedGoogle Scholar
• Ahrén B. Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vasc Health Risk Manag 2013;9:155-63
   PubMedGoogle Scholar
• Khunti K, Fisher H, Paul S, et al. Severe hypoglycaemia requiring emergency medical assistance by ambulance services in the East Midlands: a retrospective study. Primary Care Diabetes 2013;7:159-65
   PubMed Web of Science ®Google Scholar
• Brod M, Christensen T, Thomsen TL, et al. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health 2011;14:665-71
   PubMed Web of Science ®Google Scholar
• Rhoads GG, Orsini LS, Crown W, et al. Contribution of hypoglycaemia to medical care expenditures and short-term disability in employees with diabetes. J Occup Environ Med 2005;47:447-52
   PubMed Web of Science ®Google Scholar
• Lewis JD, Schinnar R, Bilker WB, et al. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007;16:393-401
   PubMed Web of Science ®Google Scholar